Trusted Press Release Distribution   Plans | Login    

Briefing Search


Author Details
Pareesh Phulkar

Bookmark and Share
Chemotherapy Devices Market Segmentation and Analysis by Recent Trends 2026
Chemotherapy is most often administrated via a vein (intravenously) using devices such as catheter and ports.

Chemotherapy Devices Mark, 9/13/2019 - Chemotherapy is most often administrated via a vein (intravenously) using devices such as catheter and ports. Long-term central venous access devices are essential for the management of cancer patients, as they minimize the discomfort of frequent venipuncture and cannulation. A catheter reduce the number of times to insert a needle in patient vein. According to the WHO 2017 report, in most upper and middle income countries, the chemotherapy dosage for some treatments and for patients with metastatic diseases is done using implantable central venous catheters or peripherally inserted central catheters (PICC).

Get PDF Brochure of This Business Report:

Manufacturers in the chemotherapy devices market are focused on technological advancements in devices. For instance, in May 2018, Advanced Chemotherapy Technologies announced development of an implant, about the size of a large coin for direct delivery of chemo agents into the pancreas. In 2017, RenovoRx received FDA approval for RenovoCath dual-balloon infusion catheter to include the delivery of chemotherapeutics.

Increasing incidences of different cancers worldwide is the major factor driving chemotherapy devices market growth. According to the World Health Organization (WHO), 2017, nearly 1 in 6 deaths occur due to cancer globally and around 70% of deaths from cancer occur in low- and middle-income economies. According to Breast Cancer Organization, in 2017, approximately 252,710 new cases of breast cancer were identified in the U.S., of which 63,410 cases were of non-invasive breast cancer.

Moreover, increasing government and private funding coupled with rising disposable income is also projected to drive chemotherapy devices market growth. According to the National Cancer Institute 2016 report, an estimated national expenditures for cancer care in the U.S. in 2017, were US$ 147.3 billion. Costs are likely to increase over the forecast period, as the population ages and cancer prevalence increases. However, not all chemotherapy patient requires a venous access device. For some chemotherapy treatment plans, the inconvenience of implanting and accessing a VAD can outweigh the benefits.

Key players operating in the global chemotherapy devices market include Advanced Chemotherapy Technologies, Baxter International, Becton, Dickinson, B. Braun, Fresenius Kabi, Halyard Health, ICU Medical, Moog Inc., Micrel Medical, Smiths Group, Terumo Corporation, and Zyno Medical

Browse more detail information about:

FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.